Year None2022202120202019201820172016 Date Latest Press Release January 6, 2022 Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones January 3, 2022 Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference December 21, 2021 Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection December 15, 2021 Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients December 1, 2021 Eiger BioPharmaceuticals Announces Presentations at Upcoming HEP DART 2021 Meeting November 10, 2021 Eiger BioPharmaceuticals to Participate in Upcoming November 2021 Investor Conferences November 4, 2021 Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update November 2, 2021 Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15 November 1, 2021 Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV October 21, 2021 Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2021 Financial Results and Business Update on Thursday, November 4 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
